Background After the MERINO trial with piperacillin/tazobactam, the efficacy of β-
lactam/tazobactam combinations in serious infections involving extended-spectrum β …

Background Few data are reported in the literature about the outcome of patients with
severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections …

The effectiveness of piperacillin/tazobactam for managing nosocomial pneumonia caused
by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is unknown. To …

Objectives The increase in infections caused by drug-resistant ESBL-producing
Enterobacteriaceae (ESBL-ENT) is a global concern. The characteristics and outcomes of …

Background This antimicrobial surveillance study reports in vitro antimicrobial activity and
susceptibility data for a panel of agents against respiratory isolates of Enterobacterales and …

Background Carbapenem antibiotics are considered the treatment of choice for serious
extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria (GNB) …

Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum β-
lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered …

Hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to extended-
spectrum β-lactamase–producing Enterobacteriaceae (ESBL-PE) represent a growing …

Purpose. Highly resistant Gram‐negative bacterial infections are associated with high
mortality. Increasing resistance to standard therapy illustrates the need for alternatives when …

Purpose To investigate the clinical significance of infection-related ventilator-associated
complications (IVAC) and their impact on carbapenem consumption in mechanically …